140PD: LUX-Lung 7: A Phase IIb, Global, Randomised, Open-Label Trial of Afatinib vs Gefitinib as First-Line Treatment for Patients (Pts) With Advanced Non-Small Cell Lung Cancer (NSCLC) Harbouring Activating EGFR Mutations

Journal of Thoracic Oncology - United States

doi 10.1016/s1556-0864(16)30250-7